Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

AMSTERDAM, The Netherlands, August 25, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

Highlights

  • Glybera®:
    • Data showing Glybera produces significant reduction in risk of pancreatitis in LPLD patients presented at European Atherosclerosis Society Meeting
    • CHMP does not consider Glybera approvable at this time
    • Chylomicrons now validated as biomarker for Glybera efficacy; data presented at American Society of Gene and Cell Therapy annual meeting
    • AMT generating further chylomicron data from existing treated patients to support re-examination process
    • Submitted for re-examination, outcome expected before end 2011
  • Collaboration with Institut Pasteur-led Consortium to develop Sanfilippo B gene therapy product for cGMP manufactured material; worth up to € 1.8 million to AMT
  • € 1.1 million funding for Acute Intermittent Porphyria gene therapy product as part of EU Consortium
  • Grant from Dutch Parents Association for Duchenne Muscular Dystrophy gene therapy
  • Appointment of Dr. Carlos R. Camozzi as Chief Medical Officer
  • Key financial figures in line with guidance
  • Cash & cash equivalents of € 9.1 million at June 30, 2011, in line with budget

"We have moved quickly and have already filed an application for re-examination of Glybera, after the initial disappointment with the CHMP opinion in June. We are continuing to collect more data to show that there is a long-term reduction in the incidence of pancreatitis in treated patients.  We will be able to generate the additional data required from the existing treated patients, and the data will come from a trial which we had already pla
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and ... third quarter 2014 financial results on Thursday, November ... team will host a live conference call and ... financial results and provide a business update. ...
(Date:10/30/2014)... CA (PRWEB) October 30, 2014 ... today that they have manually curated public data source ... non profit customers. the data is now available ... curates and unifies public and internal data sources for ... and knowledge out of the data that becomes more ...
(Date:10/30/2014)... Ras Al Khaimah, UAE (PRWEB) October 30, 2014 ... the appointment of Dr. James A. Manganello, Chairman of the ... (NSCEC) of The Bahamas. The appointment was made by ... The Bahamas on September 24th, 2014. , More ... Cell Therapy and Research Bill , Prime Minister Perry Christie ...
(Date:10/30/2014)... The severe flooding that devastated a wide swath of ... the bridges, roads and other infrastructure had been upgraded ... University of Colorado Denver. , "People need to understand ... PhD, associate professor of structural engineering at the CU ... author the study. "There is an assumption that a ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2
... ... Capital,s client Neuren Pharmaceuticals Ltd (ASX:NEU) has agreed an AU$6.7 mil convertible note private ... as Neuren,s exclusive placement agent and advisor. , ... New York (PRWEB) November 23, 2009 -- The independent ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced that it has ... common stock will be,suspended as of November 30, 2009 and a ... will remove deCODE,s common stock,from listing on Nasdaq, unless the company ...
... ... deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced the approval of all of ... Delaware,(the "Bankruptcy Court"). deCODE last week filed a voluntary petition for,relief under ... The orders issued by the Bankruptcy Court allow ...
Cached Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
(Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... developed a small-molecule inhibitor of a protein that plays ... they show that the inhibitor can halt the growth ... culture. The findings are reported in companion papers reported ... Jan-Michael Peters of the Research Institute of Molecular Pathology ...
... developed at the University of Toronto is revealing biochemical ... could one day pave the way for pharmaceutical applications. ... issue of Molecular Cell describes how U of T ... test for proteins that play an important role in ...
... popular game fish mistaken by scientists for a dog ... reefs of the Abrolhos region of the South Atlantic ... discovery of Lutjanus alexandrei, a new snapper species that ... of Conservation International (CI) and Kenyon Lindeman of Environmental ...
Cached Biology News:New protein inhibitor impedes growth of cancerous cells 2Technology reveals 'lock and key' proteins behind diseases 2New species of snapper discovered in Brazil 2
... mg/L sodium pyruvate, 50 mg/L streptomycin sulfate, ... calcium chloride, and magnesium chloride. The use ... tissue culture is generally attributed to early ... Ringer developed a solution of inorganic salts ...
... dramatic breakthrough in accurate, small-volume bulk dispensing. Dispensing ... micro 1 has unique advantages not found in ... never needs re-calibration as do other 1mL dispensers. ... LCD Display , Graphical Row Selection , 96-,384- ...
... Rabbit polyclonal to Rad51 ( Abpromise ... Antigen: Synthetic peptide: ... N terminal amino acids 15-29 of ... Gene ID: 5888 ...
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
Biology Products: